Floatz logo

Entinostat

Stage IIIA Non-Small Cell Lung Cancer

Syndax PharmaceuticalsSmall moleculePhase 2Dormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Stage IIIA Non-Small Cell Lung Cancer cohort.

Asset / SponsorPhaseRating
18f-fspg
Andrei Iagaru
Phase 2B

Same molecule, other indications

Entinostat is also rated in:

triple-negative breast carcinomaDormant
B
Indicative ·
63 / 100
View asset →
myelodysplastic syndromeDormant
B
Indicative ·
62 / 100
View asset →
acute myeloid leukemiaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →